Alto Neuroscience (ANRO) Earnings Date, Estimates & Call Transcripts $3.06 -0.01 (-0.33%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$3.06 0.00 (-0.16%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alto Neuroscience Earnings Summary Alto Neuroscience issued Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.53, which topped the consensus estimate of -$0.59 by $0.06. With a trailing EPS of -$2.34, Alto Neuroscience's earnings are expected to grow next year, from ($2.54) to ($2.39) per share. Upcoming Q2 Earnings DateAug. 12Before Market OpensEstimatedConsensus EPS (May. 13) -$0.59 Actual EPS (May. 13) -$0.53 Beat By $0.06 Q1 2025 Earnings ResourcesQ1 2025 Earnings Report Press Release (8-K) Quarterly Report (10-Q)ANRO Upcoming EarningsAlto Neuroscience's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Alto Neuroscience Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alto Neuroscience and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataANRO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. Alto Neuroscience Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.67-$0.45-$0.57Q2 20253-$0.68-$0.50-$0.58Q3 20253-$0.71-$0.56-$0.66Q4 20253-$0.73-$0.58-$0.68 FY 2025 12 -$2.79 -$2.09 -$2.48 Q1 20263-$0.82-$0.54-$0.64Q2 20263-$0.84-$0.55-$0.65Q3 20263-$0.86-$0.44-$0.62Q4 20263-$0.67-$0.45-$0.57 Alto Neuroscience Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/12/2025(Estimated)--------5/13/2025Q1 2025-$0.59-$0.53+$0.06-$0.56--3/20/2025Q4 2024-$0.65-$0.56+$0.09-$0.56--11/12/2024--$0.67-$0.62+$0.05-$0.62--8/13/2024Q2 2024-$0.67-$0.60+$0.07-$0.60--5/14/2024Q1 2024-$0.46-$0.76 -$0.30-$0.76-- Alto Neuroscience Earnings - Frequently Asked Questions When is Alto Neuroscience's earnings date? Alto Neuroscience has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 12th, 2025 based off last year's report dates. Learn more on ANRO's earnings history. Did Alto Neuroscience beat their earnings estimates last quarter? In the previous quarter, Alto Neuroscience (NYSE:ANRO) reported ($0.53) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.59) by $0.06. Learn more on analysts' earnings estimate vs. ANRO's actual earnings. How much profit does Alto Neuroscience generate each year? Alto Neuroscience (NYSE:ANRO) has a recorded net income of -$61.43 million. ANRO has generated -$2.34 earnings per share over the last four quarters. What is Alto Neuroscience's EPS forecast for next year? Alto Neuroscience's earnings are expected to grow from ($2.54) per share to ($2.39) per share in the next year. More Earnings Resources from MarketBeat Related Companies ADC Therapeutics Earnings Neumora Therapeutics Earnings Ocugen Earnings Heron Therapeutics Earnings Kodiak Sciences Earnings Corvus Pharmaceuticals Earnings Benitec Biopharma Earnings Sagimet Biosciences Earnings Atea Pharmaceuticals Earnings Cardiff Oncology Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Microsoft Blasts Past Earnings—What’s Next for MSFT?Visa Beats Q3 Earnings Expectations, So Why Did the Market Panic?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?RCL Stock Sinks After Earnings—Is a Buying Opportunity Ahead?Amazon's Pre-Earnings Setup Is Almost Too Clean—Red Flag? This page (NYSE:ANRO) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
